BioSpace News Archive

Tango Therapeutics, Inc. announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics’ Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units to a new employee under Tango Therapeutics’ 2023 Inducement Plan.

Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 90,100 shares of common stock of Spyre to 3 non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”) today reported its financial results for the full year ended December 31, 2023 and outlined recent corporate and clinical development highlights.

PANTHERx®Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Edenbridge Pharmaceuticals for the distribution of Yargesa® (miglustat) capsules, the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

Zentalis® Pharmaceuticals, Inc. announced that on April 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 105,950 shares of the Company’s common stock to four newly hired employees.

BrainStorm Cell Therapeutics Inc. today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

Xcell Biosciences Inc. today announced it has added new elements to its research collaboration agreement with Labcorp, a global leader of innovative and comprehensive laboratory services.

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer.

Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that VIGPODER ™ (vigabatrin) for oral solution, USP , a treatment for appropriate patients with infantile spasms (IS), is now available.